Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idiopathic sudden sensorineural hearing loss treatment by infliximab injection
2007-004074-10Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of infliximab in idiopathic sudden sensorineural hearing loss (ISSNHL) and Ear Disorder, sponsored by Policlinico Gemelli. Primary endpoint: Therapeutic effect on idiopathic sudden sensorineural hearing loss. Started Jan 2008; status: terminated.
02
Drugs
infliximab
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)Ear Disorder
Beyond the preview
Go deeper on 2007-004074-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004074-10.